Emerging therapies for treatment of multiple sclerosis

about

Current and emerging therapies in multiple sclerosis: a systematic review Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis In Vivo Optical Imaging of Myelination Events in a Myelin Basic Protein Promoter-Driven Luciferase Transgenic Mouse Model.

P2860

Q29010983-37473579-11A7-454A-84B3-A078AB415F7F Q37502636-91C40216-3851-4977-BCB5-D546A41EDBDA Q55346781-3F049823-1BA4-4795-AE50-17C4B21B6755

P2860

Emerging therapies for treatment of multiple sclerosis

Item

http://www.wikidata.org/entity/Q35557390

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Emerging therapies for treatment of multiple sclerosis

@ast

Emerging therapies for treatment of multiple sclerosis

@en

type

Item

label

Emerging therapies for treatment of multiple sclerosis

@ast

Emerging therapies for treatment of multiple sclerosis

@en

prefLabel

Emerging therapies for treatment of multiple sclerosis

@ast

Emerging therapies for treatment of multiple sclerosis

@en

P1476

Emerging therapies for treatment of multiple sclerosis

@en

P2093

Augusto A Miravalle

http://www.w3.org/2001/XMLSchema#string

John R Corboy

http://www.w3.org/2001/XMLSchema#string

P2860

The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

LINGO-1 negatively regulates myelination by oligodendrocytes

Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions.

P304

53-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JIR.S6558

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22096357

http://www.w3.org/2001/XMLSchema#string

P932

3218736

http://www.w3.org/2001/XMLSchema#string

Emerging therapies for treatment of multiple sclerosis

about

P2860

P2860

Emerging therapies for treatment of multiple sclerosis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932